Ran Nussbaum - 08 Jun 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
08 Jun 2022
Net transactions value
$0
Form type
4
Filing time
10 Jun 2022, 15:36:16 UTC
Previous filing
28 Feb 2023
Next filing
17 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Award $0 +6,817 $0.000000 6,817 08 Jun 2022 Ordinary Shares 6,817 $7.06 by Pontifax (Israel) III Limited Partnership F1
transaction URGN Stock Option (right to buy) Award $0 +3,183 $0.000000 3,183 08 Jun 2022 Ordinary Shares 3,183 $7.06 By Pontifax Cayman III Limited Partnership F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year.